Basal Insulin Initiation in Elderly Patients with Hyperglycemia

Assessment and Treatment Approach

For elderly patients (>65 years), treatment decisions should prioritize safety and quality of life, with less stringent glycemic targets to avoid hypoglycemia, according to the American Diabetes Association 1
Non-insulin medications should be optimized first in elderly patients with mild-to-moderate hyperglycemia, as recommended by the American Diabetes Association 1, 2
A stepwise approach can be considered, including ensuring metformin is optimized if not contraindicated by renal function, and adding second-line agents with low hypoglycemia risk, such as SGLT2 inhibitors, DPP-4 inhibitors, or GLP-1 receptor agonists, as suggested by the American Diabetes Association 1, 2, 3

Basal insulin should be considered when HbA1c remains significantly elevated (>9%) despite oral agents, or when fasting blood glucose is consistently elevated above 180-200 mg/dL, according to the American College of Physicians 4, 2
If insulin becomes necessary, a lower dose should be started, such as 0.1 units/kg/day, and long-acting insulin analogs, like glargine, detemir, or degludec, should be used to reduce the risk of nocturnal hypoglycemia, as recommended by the American Diabetes Association 4, 1, 6
Less stringent fasting glucose targets (90-150 mg/dL) should be set, and adequate education and support for insulin administration and hypoglycemia recognition should be provided, according to the American Diabetes Association 1, 7